Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MacroGenics (MGNX)
NASDAQ:MGNX
MacroGenics (MGNX) Stock Price & Analysis
617 Followers
MGNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.14 - $21.88
Previous Close$4.92
Volume788.56K
Average Volume (3M)2.43M
Market Cap
$308.16M
Enterprise Value$241.17M
Total Cash (Recent Filing)$100.96M
Total Debt (Recent Filing)$33.97M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 01, 2024EPS Estimate
-$0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding62,633,460
10 Day Avg. Volume1,777,228
30 Day Avg. Volume2,426,610
Standard Deviation0.32
R-Squared0.11
Alpha-0.00669
Financial Highlights & Ratios
Price to Book (P/B)1.79
Price to Sales (P/S)29.87
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.82
Enterprise Value/Gross Profit4.92
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$11.11Price Target Upside125.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
MacroGenics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Tamarack study exhibits favorable safety outcomes compared to other prostate cancer studies, with lower discontinuation rates and Grade 3+ adverse event rates.
EfficacyVobra-duo's safety profile is drastically improved with the new Q4W dosing regimen and showed a significant reduction in discontinuations and interruptions, which could lead to a boost in efficacy.
PipelineMGNX's innovative oncology therapeutics pipeline leverages advances in antibody protein engineering to pursue the most relevant modality—antibody-drug conjugates (ADCs), T cell engagers (TCEs), and bispecifics—against biologically de-risked targets.
Bears Say
Financial PerformancePT decreases from $25 to $18, driven by longer than anticipated timeline to Ph. III execution, coupled with higher OpEx spend required to exploit B7-H3 ADC potential within mCRPC and additional tumor types.
Regulatory ApprovalLowering the probability of approval for vobra duo in mCRPC to 10% from 30%.
Safety ConcernsFive events with fatal outcomes occurred during the trial.
---
Ownership Overview
31.04% Insiders
22.60% Mutual Funds
12.09% Other Institutional Investors
34.28% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $3.14 and its highest was $21.88 in the past 12 months.
What is MacroGenics’s market cap?
Currently, no data Available
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Aug 01, 2024 which is in 11 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on May 09, 2024. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.643 by -$0.197.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -$0.71.
How many shares outstanding does MacroGenics have?
MacroGenics has 62,633,460 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.643. Following the earnings report the stock price went down -77.437%.
Which hedge fund is a major shareholder of MacroGenics?
Among the largest hedge funds holding MacroGenics’s share is RA Capital Management. It holds MacroGenics’s shares valued at 31M.
---
MacroGenics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.11 (125.81% Upside)
$11.11 (125.81% Upside)
Blogger Sentiment
Bullish
MGNX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.57%
12-Months-Change
Fundamentals
Return on Equity
-21.58%
Trailing 12-Months
Asset Growth
-27.72%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
---
MGNX Earnings Call
Q1 2024
0:00 / 0:00
---
MGNX Stock 12 Month Forecast
Average Price Target
$11.11
▲(125.81% Upside)
Technical Analysis
Best Analysts Covering MGNX
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
-2.54%
reiterated a buy rating 2 months ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -2.54% per trade.
---